Vincerx Pharma (VINC) Stock Price, News & Analysis

Company Overview

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.

Key Stats

• Today's Range: $0.69 to $0.72
• 50-Day Range: $0.51 to $0.84
• 52-Week Range: $0.51 to $9.37
• Volume: 144,950 shs
• Average Volume: 681,105 shs
• Market Capitalization: $20.41 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Buy

Vincerx Pharma Stock Analysis - MarketRank™

Vincerx Pharma scored higher than 38% of companies evaluated by MarketBeat, and ranked 777th out of 1,017 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Vincerx Pharma.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Vincerx Pharma are expected to grow in the coming year, from ($0.49) to ($0.46) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Vincerx Pharma is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Vincerx Pharma is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Vincerx Pharma has a P/B Ratio of 1.32. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.34% of the outstanding shares of Vincerx Pharma have been sold short.

Short Interest Ratio / Days to Cover

Vincerx Pharma has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Vincerx Pharma has recently decreased by 1.66%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vincerx Pharma does not currently pay a dividend.

Dividend Growth

Vincerx Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.34% of the outstanding shares of Vincerx Pharma have been sold short.

Short Interest Ratio / Days to Cover

Vincerx Pharma has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Vincerx Pharma has recently decreased by 1.66%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: N/A

News Sentiment

Vincerx Pharma has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.

Search Interest

7 people have searched for VINC on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Vincerx Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

22.90% of the stock of Vincerx Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

44.02% of the stock of Vincerx Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

VINC Stock Analysis - Frequently Asked Questions

How have VINC shares performed this year?

Vincerx Pharma's stock was trading at $1.18 at the beginning of 2024. Since then, VINC stock has decreased by 41.7% and is now trading at $0.6877.
View the best growth stocks for 2024 here.

How were Vincerx Pharma's earnings last quarter?

Vincerx Pharma, Inc. (NASDAQ:VINC) released its quarterly earnings results on Thursday, August, 8th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.12.

Who are Vincerx Pharma's major shareholders?

Top institutional shareholders of Vincerx Pharma include Armistice Capital LLC (6.70%), Point72 Asset Management L.P. (2.27%) and Marshall Wace LLP (1.11%). Insiders that own company stock include Ahmed Md Hamdy, Raquel E Izumi, Alexander A Seelenberger, Laura I Bushnell and Tom C Thomas.
View institutional ownership trends.

How do I buy shares of Vincerx Pharma?

Shares of VINC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

• Last Earnings: 8/08/2024
• Today: 9/19/2024
• Next Earnings (Estimated): 11/12/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VINC
• CUSIP: N/A
• CIK: 1796129
• Web: vincerapharma.com
• Phone: 650-800-6676
• Fax: N/A
• Employees: 60
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.79)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-40,160,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -226.84%
• Return on Assets: -122.94%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.43
• Quick Ratio: 3.43

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.52 per share
• Price / Book: 1.32

Miscellaneous

• Outstanding Shares: 29,672,000
• Free Float: 22,877,000
• Market Cap: $20.41 million
• Optionable: Not Optionable
• Beta: 1.51